SANTA CLARA, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) and NimbleGen Systems Inc. announced today that NimbleGen has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering the manufacture, use and sales of nucleic acid microarrays and related products and services in the research field. Financial details of the license were not disclosed.
